[13] In the animal studies and in one human case report, it was found to potentially be associated with developing osteosarcoma in test subjects after over two years of use.

[15] The tumors found in the rat studies were located on the end of the bones which grew after the injections began.

[17] This risk was considered by the FDA as "extremely rare" (1 in 100,000 people)[18] and is only slightly more than the incidence in the population over 60 years old (0.4 in 100,000).

[13][23] Teriparatide (Forteo) was approved by the FDA in November 2002, for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture.

[1] Recombinant teriparatide is sold by Eli Lilly and Company under the brand names Forteo and Forsteo.

In June 2020, Alvogen, Inc, Pfenex Inc.'s commercialization partner, launched teriparatide injection (Bonsity) in the United States.

[1] Teriparatide injection is pharmaceutically equivalent to Forteo (that is, has the same active ingredient in the same strength, dosage form and route of administration) and has been shown to have comparable bioavailability.

[33][2] Teriparatide is undergoing a clinical trial with zoledronic acid as a treatment for osteogenesis imperfecta to reduce the risk of broken bones.

The first such trial was published by Leder et al. in Lancet in 2013 with further data subsequently published in JCEM in a trial of post menopausal osteoporotic women demonstrating larger bone mineral density increases in the spine and hip with combination therapy compared to either drug alone.